Bone Metastases, Brain Metastases, Head and Neck Cancer, Lung Cancer
Conditions
Keywords
tumor delineation, organs at risk delineation, dual-energy CT, DECT, radiotherapy
Brief summary
The primary aim of this clinical study, 'Dual Energy CT - a tool for delineation of tumor and organs at risk in radiotherapy' (DART) is to evaluate whether dual-energy CT (DECT) is at least as effective as magnetic resonance imaging (MRI) in delineating both tumors and organs at risk (OARs) in patients referred for radiotherapy (RT). This primary aim will be explored in patient groups where the performance of DECT for RT has been described in the literature (but mostly based on signal-to-noise ratio and/or contrast-to-noise ratio), such as brain metastases (sub-cohort 'DART Brain') and head and neck cancer (sub-cohort 'DART H&N'). Additionally, DART will explore diagnoses not yet studied in the literature, such as bone metastases (sub-cohort 'DART Bone'). If DECT could be demonstrated to achieve delineations for RT in both tumors and OARs that are equally accurate as those based on MRI, it could offer significant advantages by being faster and more cost-effective, making DECT a valuable alternative to MRI in clinical practice. As a secondary aim, the study will evaluate whether DART offers benefits when added to standard RT imaging for tumor and OAR delineation: (1) For lung cancer patients (sub-cohort 'DART Lung'), where MRI scans are typically not valuable due to tumor motion caused by breathing, 'DART Lung' will assess whether DECT performed in breath-hold provides added value compared to the single-energy CT (SECT) scan conducted during free breathing, as used in current clinical practice. (2) For head and neck cancer patients, 'DART H&N' will evaluate whether DECT offers added value compared to the positron emission tomography (PET)/CT scan currently used in clinical practice.
Detailed description
A detailed description of the study is provided in the uploaded document 'Study Protocol with Statistical Analysis Plan'.
Interventions
DIAGNOSTIC_TESTDual-energy CT (DECT)
Additional DECT scan performed for tumor and OAR delineation.
DRUGIodine-based contrast agent
Administered intravenously with DECT for enhanced imaging.
DIAGNOSTIC_TESTMagnetic Resonance Imaging (MRI)
Additional MRI scan performed for tumor and OAR delineation.
DRUGGadolinium-based contrast agent
Administered intravenously with MRI for enhanced imaging.
Sponsors
Copenhagen University Hospital at Herlev
Odense University Hospital
Aalborg University Hospital
Study design
Observational model
COHORT
Time perspective
PROSPECTIVE
Eligibility
Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No
Inclusion criteria
* ECOG performance status (PS) 0-2 * Assessed to be able to complete the protocol scanning regime * Referred for RT * For head and neck cancer patients, a PET/CT scan must have been performed during the diagnostic evaluation for cancer * Signed informed consent
Exclusion criteria
* Pregnancy * Previous RT in the same anatomical area now referred for RT * Previous surgery in the same anatomical area now referred for RT * Participation in conflicting protocols * If relevant for the protocol scanning regime: Allergic to contrast agent * If relevant for the protocol scanning regime: Contraindication to iodine-based contrast agent for CT (as determined by the physician) * If relevant for the protocol scanning regime: Contraindication to Gadolinium-based contrast agent for MRI (as determined by the physician) * If relevant for the protocol scanning regime: Contraindication for MRI (pacemaker, metal, non-MRI, compatible implants etc.) * Incapable of understanding the patient information
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Inter-observer variability (geometric differences in volume and surface) of manual tumor and OAR delineations on DECT compared with SECT/MRI. | Baseline (time of imaging before radiotherapy planning) | For patients enrolled in cohorts 'DART Brain', 'DART Bone' and 'DART H&N', the accuracy of manual delineations of tumors and OARs on DECT scans will be compared to those manually performed on a combination of SECT and MRI scans for each patient. For patients enrolled in 'DART H&N' the comparison will also be done to the PET/CT scan. A reduction in inter-observer variability in delineations will serve as an indicator of improved contour accuracy for both tumors and OARs. Inter-observer variability for tumor and OAR delineations on DECT and SECT/MRI scans, respectively, will be measured as geometric differences between individual manual delineations and consensus structures for each tumor and OAR. Consensus structures will be generated on both DECT and SECT/MRI scans using the STAPLE function with a 50% agreement threshold. Variations relative to the consensus structures will be reported using various metrics, including volume and surface differences. |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Qualitative image-quality assessment of tumors and OARs using a Likert scale (or comparable method) for DECT compared with SECT/MRI. | Baseline (time of imaging before radiotherapy planning) | The secondary outcome will be measured in all patient cohorts ('DART Brain', 'DART Bone', 'DART H&N', and 'DART Lung'). Image-quality for tumors and OARs will be evaluated qualitatively by experienced oncologists using a Likert scale or comparable method, and evaluations will be made and reported between DECT and SECT/MRI scans (and, for patients enrolled in 'DART H&N', also PET/CT scans). |
Countries
Denmark
Contacts
Primary ContactHella MB Sand, Medical Physicist, MSc
Backup ContactLaurids Ø Poulsen, Clinical Oncologist, MD, PhD
Outcome results
None listed